Entering text into the input field will update the search result below

Can-Fite delays topline data from late-stage psoriasis trial for lead asset

Mar. 08, 2022 7:30 AM ETCan-Fite BioPharma Ltd. (CANF)AMGNBy: Dulan Lokuwithana, SA News Editor1 Comment

Delay Road Sign

GOCMEN/iStock via Getty Images

  • Can-Fite BioPharma (NYSE:CANF), a clinical-stage biopharmaceutical company, is trading ~8% lower in the pre-market Tuesday after announcing a delay for a key data readout for the company’s lead candidate Piclidenoson from a late-stage trial in psoriasis.
  • Piclidenoson, an

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.